The 21-aminosteroid compounds are potent lipid peroxidation inhibitors belonging to a new class of antioxidants given the collective name of "lazaroids". They protect cells from oxidative damage induced by oxygen-based free radicals in a variety of in vitro and in vivo test systems. U-83836E is one of the second-generation lazaroids that are based on a non steroidal structure characterized by a ring portion of alpha-tocopherol bonded with various amine groups. We investigated the ability of U-83836E to reduce myocardial damage in rats undergoing left coronary artery occlusion for 60 min followed by 6 hours of reperfusion. This ischemia/reperfusion model produced wide heart necrosis, membrane lipid peroxidation, ventricular arrhythmias, tissue neutrophil infiltration and a marked decrease in endogenous antioxidants. Intravenous administration of U-83836E, (7.5, 15 and 30 mg/kg) at onset of reperfusion, reduced myocardial necrosis, expressed as a percentage of either the area at risk or the total left ventricle (p < 0.001), improved haemodynamic conditions by decreasing ventricular arrhythmias (p < 0.005), limited membrane lipid peroxidation (evaluated by assessing conjugated dienes, p < 0.001; and 4-hydroxynonenal, p < 0.001) restored the endogenous antioxidants vitamin E (p < 0.001), and superoxide dismutase (pt < 0.001). Furthermore, the lazaroid inhibited the derimental hydroxyl radical formation (p < 0.001), evaluated indirectly by a trapping agent and reduced heart neutrophil infiltration, measured by testing cardiac tissue elastase (p < 0.001) that is released from the stimulated granulocytes at the site of injury. These data suggest that this compound could be a new useful tool to study the mechanisms of oxidative damage during myocardial infarction.
No takes yet. Share an insight, caveat, or question.
Campo et al. (1997) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: